Targeted synthetic pharmacotherapy for psoriatic arthritis: state of the art

References

• Chimenti MS, Caso F, Alivernini S, et al. Amplifying the concept of psoriatic arthritis: the role of autoimmunity in systemic psoriatic disease. Autoimmun Rev. 2019;18:565–575.
   PubMed Web of Science ®Google Scholar
• FitzGerald O, Haroon M, Giles JT, et al. Concepts of pathogenesis in psoriatic arthritis: genotype determines clinical phenotype. Arthritis Res Ther. 2015;17:115.
   PubMed Web of Science ®Google Scholar
• Veale DJ, Fearon U. The pathogenesis of psoriatic arthritis. Lancet. 2018;391:2273–2284.
   PubMed Web of Science ®Google Scholar
• Caso F, Costa L, Nucera V, et al. From autoinflammation to autoimmunity: old and recent findings. Clin Rheumatol. 2018;37:2305–2321.
   PubMed Web of Science ®Google Scholar
• Scarpa R, Caso F, Costa L, et al. Psoriatic disease: clinical staging. J Rheumatol Suppl. 2015;93:24–26.
   PubMedGoogle Scholar
• Lambert JR, Wright V. Eye inflammation in psoriatic arthritis. Ann Rheum Dis. 1976;35:354–356.
   PubMed Web of Science ®Google Scholar
• Rosenbaum JT. Uveitis in spondyloarthritis including psoriatic arthritis, ankylosing spondylitis, and inflammatory bowel disease. Clin Rheumatol. 2015;34:999–1002.
   PubMed Web of Science ®Google Scholar
• Ciccia F, Guggino G, Ferrante A, et al. Interleukin-9 overexpression and Th9 polarization characterize the inflamed gut, the synovial tissue, and the peripheral blood of patients with psoriatic arthritis. Arthritis Rheumatol. 2016;68:1922–1931.
   PubMed Web of Science ®Google Scholar
• Costa L, Caso F, D’Elia L, et al. Psoriatic arthritis is associated with increased arterial stiffness in the absence of known cardiovascular risk factors: a case control study. Clin Rheumatol. 2012;31:711–715.
   PubMed Web of Science ®Google Scholar
• Navarini L, Margiotta DPE, Costa L, et al. Performance and calibration of the algorithm ASSIGN in predicting cardiovascular disease in Italian patients with psoriatic arthritis. Clin Rheumatol. 2019;38:971–976.
   PubMed Web of Science ®Google Scholar
• Eder L, Dey A, Joshi AA, et al. Cardiovascular diseases in psoriasis and psoriatic arthritis. J Rheumatol Suppl. 2019;95:20–27.
   PubMedGoogle Scholar
• Caso F, Del Puente A, Oliviero F, et al. Metabolic syndrome in psoriatic arthritis: the interplay with cutaneous involvement. Evidences from literature and a recent cross-sectional study. Clin Rheumatol. 2018;37:579–586.
   PubMed Web of Science ®Google Scholar
• Caso F, Postiglione L, Covelli B, et al. Pro-inflammatory adipokine profile in psoriatic arthritis: results from a cross-sectional study comparing PsA subset with evident cutaneous involvement and subset “sine psoriasis”. Clin Rheumatol. 2019;38:2547–2552.
   PubMed Web of Science ®Google Scholar
• Costa L, Caso F, Ramonda R, et al. Metabolic syndrome and its relationship with the achievement of minimal disease activity state in psoriatic arthritis patients: an observational study. Immunol Res. 2015;61:147–153.
   PubMed Web of Science ®Google Scholar
• Costa L, Caso F, Atteno M, et al. Impact of 24-month treatment with etanercept, adalimumab, or methotrexate on metabolic syndrome components in a cohort of 210 psoriatic arthritis patients. Clin Rheumatol. 2014;33:833–839.
   PubMed Web of Science ®Google Scholar
• Feld J, Nissan S, Eder L, et al. Increased prevalence of metabolic syndrome and adipocytokine levels in a psoriatic arthritis cohort. J Clin Rheumatol. 2018;24:302–307.
   PubMed Web of Science ®Google Scholar
• Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. 2017;376:957–970.
   PubMed Web of Science ®Google Scholar
• Napolitano M, Caso F, Scarpa R, et al. Psoriatic arthritis and psoriasis: differential diagnosis. Clin Rheumatol. 2016;35:1893–1901.
   PubMed Web of Science ®Google Scholar
• Moll JM, Wright V. Psoriatic arthritis. Semin Arthritis Rheum. 1973;3:55–78.
   PubMedGoogle Scholar
• Scarpa R, Caso F, Costa L, et al. Psoriatic disease 10 years later. J Rheumatol. 2017;44:1298–1301.
   PubMed Web of Science ®Google Scholar
• Lubrano E, Parsons WJ, Marchesoni A, et al. The definition and measurement of axial psoriatic arthritis. J Rheumatol Suppl. 2015;93:40–42.
   PubMedGoogle Scholar
• Gladman DD, Antoni C, Mease P, et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005;64:ii14–7.
   PubMed Web of Science ®Google Scholar
• Soscia E, Sirignano C, Catalano O, et al. New developments in magnetic resonance imaging of the nail unit. J Rheumatol Suppl. 2012;89:49–53.
   PubMedGoogle Scholar
• Soscia E, Scarpa R, Cimmino MA, et al. Magnetic resonance imaging of nail unit in psoriatic arthritis. J Rheumatol Suppl. 2009;83:42–45.
   PubMedGoogle Scholar
• Haddad A, Johnson SR, Somaily M, et al. Psoriatic arthritis mutilans: clinical and radiographic criteria. A systematic review. J Rheumatol. 2015;42:1432–1438.
   PubMed Web of Science ®Google Scholar
• Kehl AS, Corr M, Weisman MH. Review: enthesitis: new insights into pathogenesis, diagnostic modalities, and treatment. Arthritis Rheumatol. 2016;68:312–322.
   PubMed Web of Science ®Google Scholar
• Gladman DD, Ziouzina O, Thavaneswaran A, et al. Dactylitis in psoriatic arthritis: prevalence and response to therapy in the biologic era. J Rheumatol. 2013;40:1357–1359.
   PubMed Web of Science ®Google Scholar
• Girolimetto N, Macchioni P, Tinazzi I, et al. Predominant ultrasonographic extracapsular changes in symptomatic psoriatic dactylitis: results from a multicenter cross-sectional study comparing symptomatic and asymptomatic hand dactylitis. Clin Rheumatol. 2019. DOI:10.1007/s10067-019-04683-2.
   Web of Science ®Google Scholar
• Girolimetto N, Macchioni P, Tinazzi I, et al. Ultrasonographic evidence of predominance of acute extracapsular and chronic intrasynovial patterns in 100 psoriatic hand dactylitis. J Rheumatol. 2019 May 15;ii: jrheum.190046. DOI:10.3899/jrheum.190046.
   PubMed Web of Science ®Google Scholar
• Girolimetto N, Costa L, Mancarella L, et al. Symptomatic psoriatic dactylitis is associated with ultrasound determined extra-synovial inflammatory features and shorter disease duration. Clin Rheumatol. 2019;38:903–911.
   PubMed Web of Science ®Google Scholar
• Brockbank JE, Stein M, Schentag CT, et al. Dactylitis in psoriatic arthritis: a marker for disease severity? AnnRheum Dis. 2005;64:188–190.
   PubMed Web of Science ®Google Scholar
• Giacomelli R, Afeltra A, Alunno A, et al. Guidelines for biomarkers in autoimmune rheumatic diseases – evidence based analysis. Autoimmun Rev. 2019;18:93–106.
   PubMed Web of Science ®Google Scholar
• Caso F, Costa L, Atteno M, et al. Simple clinical indicators for early psoriatic arthritis detection. Springerplus. 2014;3:759.
   PubMed Web of Science ®Google Scholar
• Tillett W, Costa L, Jadon D, et al. The ClASsification for Psoriatic ARthritis (CASPAR) criteria – a retrospective feasibility, sensitivity, and specificity study. J Rheumatol. 2012;39:154–156.
   PubMed Web of Science ®Google Scholar
• Caso F, Tasso M, Chimenti MS, et al. Late-onset and elderly psoriatic arthritis: clinical aspects and management. Drugs Aging. 2019;36:909–925.
   PubMed Web of Science ®Google Scholar
• Ficjan A, Husic R, Gretler J, et al. Ultrasound composite scores for the assessment of inflammatory and structural pathologies in Psoriatic Arthritis (PsASon-Score). Arthritis Res Ther. 2014;16:476.
   PubMed Web of Science ®Google Scholar
• Fiocco U, Stramare R, Coran A, et al. Vascular perfusion kinetics by contrast-enhanced ultrasound are related to synovial microvascularity in the joints of psoriatic arthritis. Clin Rheumatol. 2015;34:1903–1912.
   PubMed Web of Science ®Google Scholar
• Tan AL, Fukuba E, Halliday NA, et al. High-resolution MRI assessment of dactylitis in psoriatic arthritis shows flexor tendon pulley and sheath-related enthesitis. Ann Rheum Dis. 2015;74:185–189.
   PubMed Web of Science ®Google Scholar
• D’Agostino MA, Aegerter P, Bechara K, et al. How to diagnose spondyloarthritis early? Accuracy of peripheral enthesitis detection by power Doppler ultrasonography. Ann Rheum Dis. 2011;70:1433–1440.
   PubMed Web of Science ®Google Scholar
• Fiocco U, Sfriso P, Oliviero F, et al. Blockade of intra-articular TNF in peripheral spondyloarthritis: its relevance to clinical scores, quantitative imaging and synovial fluid and synovial tissue biomarkers. Joint Bone Spine. 2013;80:165–170.
   PubMed Web of Science ®Google Scholar
• Sudoł-Szopińska I, Matuszewska G, Kwiatkowska B, et al. Diagnostic imaging of psoriatic arthritis. Part I: etiopathogenesis, classifications and radiographic features. J Ultrason. 2016;16:65–77.
   PubMed Web of Science ®Google Scholar
• Tucker LJ, Coates LC, Helliwell PS. Assessing disease activity in psoriatic arthritis: a literature review. Rheumatol Ther. 2019;6:23–32.
   PubMed Web of Science ®Google Scholar
• Scarpa R, Caso F. Spondyloarthritis: which composite measures to use in psoriatic arthritis? Nat Rev Rheumatol. 2018;14:125–126.
   PubMed Web of Science ®Google Scholar
• McHugh NJ. Early psoriatic arthritis. Rheum Dis Clin North Am. 2015;41:615–622.
   PubMed Web of Science ®Google Scholar
• Borman P, Toy GG, Babaoğlu S, et al. A comparative evaluation of quality of life and life satisfaction in patients with psoriatic and rheumatoid arthritis. Clin Rheumatol. 2007;26:330–334.
   PubMed Web of Science ®Google Scholar
• Sokoll KB, Helliwell PS. Comparison of disability and quality of life in rheumatoid and psoriatic arthritis. J Rheumatol. 2001;28:1842–1846.
   PubMed Web of Science ®Google Scholar
• Coates LC, Kavanaugh A, Mease PJ, et al. Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol. 2016;68:1060–1071.
   PubMed Web of Science ®Google Scholar
• Gossec L, Smolen JS, Ramiro S, et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis. 2016;75:499–510.
   PubMed Web of Science ®Google Scholar
• Gossec L, Coates LC, de Wit M, et al. Management of psoriatic arthritis in 2016: a comparison of EULAR and GRAPPA recommendations. Nat Rev Rheumatol. 2016;12:743–750.
   PubMed Web of Science ®Google Scholar
• Singh JA, Guyatt G, Ogdie A, et al. Special article: 2018 American College of Rheumatology/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis. Arthritis Care Res (Hoboken). 2019;71:2–29.
   PubMed Web of Science ®Google Scholar
• Ye W, Coates LC. Should methotrexate have any place in the treatment of psoriatic arthritis? Rheum Dis Clin North Am. 2019;45:325–339.
   PubMed Web of Science ®Google Scholar
• Scarpa R, Costa L, Atteno M, et al. Treatment options: nSAIDs and DMARDs. Advances in the management of psoriatic arthritis. Future Medicine. 2013;:63–70.
   Google Scholar
• Ocampo DV, Gladman D. Psoriatic arthritis. F1000Res. 2019. DOI:10.12688/f1000research.19144.1
   PubMedGoogle Scholar
• Costa L, Caso F, Del Puente A, et al. Incidence of malignancies in a cohort of psoriatic arthritis patients taking traditional disease modifying antirheumatic drug and tumor necrosis factor inhibitor therapy: an observational study. J Rheumatol. 2016;43:2149–2154.
   PubMed Web of Science ®Google Scholar
• Papoutsaki M, Chimenti MS, Costanzo A, et al. Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics. J Am Academy Dermatol. 2007;57:269–275.
   PubMed Web of Science ®Google Scholar
• Atteno M, Costa L, Matarese A, et al. The use of TNF-α blockers in psoriatic arthritis patients with latent tuberculosis infection. Clin Rheumatol. 2014;33:543–547.
   PubMed Web of Science ®Google Scholar
• Caso F, Cantarini L, Morisco F, et al. Current evidence in the field of the management with TNF-α inhibitors in psoriatic arthritis and concomitant hepatitis C virus infection. Expert Opin Biol Ther. 2015;15:641–650.
   PubMed Web of Science ®Google Scholar
• Costa L, Caso F, Atteno M, et al. Long-term safety of anti-TNF-α in PsA patients with concomitant HCV infection: a retrospective observational multicenter study on 15 patients. Clin Rheumatol. 2014;33:273–276.
   PubMed Web of Science ®Google Scholar
• Caso F, Costa L, Del Puente A, et al. Psoriatic arthritis and TNF inhibitors: advances on effectiveness and toxicity. Expert Opin Biol Ther. 2015;15:1–2.
   PubMed Web of Science ®Google Scholar
• Caso F, Lubrano E, Del Puente A, et al. Progress in understanding and utilizing TNF-α inhibition for the treatment of psoriatic arthritis. Expert Rev Clin Immunol. 2016;12:315–331.
   PubMed Web of Science ®Google Scholar
• Costa L, Perricone C, Chimenti MS, et al. Switching between biological treatments in psoriatic arthritis: a review of the evidence. Drugs R D. 2017;17:509–522.
   Web of Science ®Google Scholar
• Caso F, Del Puente A, Peluso R, et al. Emerging drugs for psoriatic arthritis. Expert Opin Emerg Drugs. 2016;21:69–79.
   PubMed Web of Science ®Google Scholar
• Ritchlin C, Scher JU. Strategies to improve outcomes in psoriatic arthritis. Curr Rheumatol Rep. 2019;21(12):72.
   PubMed Web of Science ®Google Scholar
• Torgutalp M, Poddubnyy D. Emerging treatment options for spondyloarthritis. Best Pract Res Clin Rheumatol. 2018;32:472–484.
   PubMed Web of Science ®Google Scholar
• McInnes IB, Mease PJ, Kirkham B, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;386:1137–1146.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Smolen JS, Behrens F, et al. A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naive patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial. Ann Rheum Dis. 2019 Sep 28. DOI:10.1136/annrheumdis-2019-215386.
   Web of Science ®Google Scholar
• Scarpa R, Costa L, Atteno M, et al. Psoriatic arthritis: advances in pharmacotherapy based on molecular target. Expert Opin Pharmacother. 2013;14:2311–2313.
   PubMed Web of Science ®Google Scholar
• Zippin JH, Chadwick PA, Levin LR, et al. Soluble adenylyl cyclase defines a nuclear cAMP microdomain in keratinocyte hyperproliferative skin diseases. J Invest Dermatol. 2010;130:1279–1287.
   PubMed Web of Science ®Google Scholar
• Schafer PH, Truzzi F, Parton A, et al. Phosphodiesterase 4 in inflammatory diseases: effects of apremilast in psoriatic blood and in dermal myofibroblasts through the PDE4/CD271 complex. Cell Signal. 2016;28:753–763.
   PubMed Web of Science ®Google Scholar
• Fiocco U, Martini V, Accordi B, et al. Ex vivo signaling protein mapping in T lymphocytes in the psoriatic arthritis joints. J Rheumatol Suppl. 2015;93:48–52.
   PubMedGoogle Scholar
• Fiocco U, Martini V, Accordi B, et al. Transcriptional network profile on synovial fluid T cells in psoriatic arthritis. Clin Rheumatol. 2015;34:1571–1580.
   PubMed Web of Science ®Google Scholar
• Fiocco U, Accordi B, Martini V, et al. JAK/STAT/PKCδ molecular pathways in synovial fluid T lymphocytes reflect the in vivo T helper-17 expansion in psoriatic arthritis. Immunol Res. 2014;58:61–69.
   PubMed Web of Science ®Google Scholar
• Costa L, Del Puente A, Peluso R, et al. Small molecule therapy for managing moderate to severe psoriatic arthritis. Expert Opin Pharmacother. 2017;18:1557–1567.
   PubMed Web of Science ®Google Scholar
• Toussirot E. New treatment options and emerging drugs for axial spondyloarthritis: biological and targeted synthetic agents. Expert Opin Pharmacother. 2017;18:275–282.
   PubMed Web of Science ®Google Scholar
• Li H, Zuo J, Tang W. Phosphodiesterase-4 inhibitors for the treatment of inflammatory diseases. Front Pharmacol. 2018;9:1048.
   PubMed Web of Science ®Google Scholar
• Chimenti MS, Triggianese P, De Martino E, et al. An update on pathogenesis of psoriatic arthritis and potential therapeutic targets. Expert Rev Clin Immunol. 2019;15:823–836.
   PubMed Web of Science ®Google Scholar
• Jammal TE, Gerfaud-Valentin M, Sève P, et al. Inhibition of JAK/STAT signaling in rheumatologic disorders: the expanding spectrum. Joint Bone Spine. 2019. DOI:10.1016/j.jbspin.2019.09.005
   PubMed Web of Science ®Google Scholar
• Sakkas LI, Zafiriou E, Bogdanos DP. Mini review: new treatments in psoriatic arthritis. Focus on the IL-23/17 axis. Front Pharmacol. 2019;10:872.
   PubMed Web of Science ®Google Scholar
• Elalouf O, Chandran V. Novel therapeutics in psoriatic arthritis. What is in the pipeline? Curr Rheumatol Rep. 2018;20:36.
   PubMed Web of Science ®Google Scholar
• Chimenti MS, Gramiccia T, Saraceno R, et al. Apremilast for the treatment of psoriasis. Expert Opin Pharmacother. 2015;16:2083–2094.
   PubMed Web of Science ®Google Scholar
• Schafer P. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochem Pharmacol. 2012;83:1583–1590.
   PubMed Web of Science ®Google Scholar
• Torres T, Puig L. Apremilast: a novel oral treatment for psoriasis and psoriatic arthritis. Am J Clin Dermatol. 2018;19:23–32.
   PubMed Web of Science ®Google Scholar
• Zerilli T, Ocheretyaner E. Apremilast (Otezla): a new oral treatment for adults with psoriasis and psoriatic arthritis. P T. 2015;40:495–500.
   PubMedGoogle Scholar
• Deeks ED. Apremilast: a review in psoriasis and psoriatic arthritis. Drugs. 2015;75:1393–1403.
   PubMed Web of Science ®Google Scholar
• Megna M, Balato A, Napolitano M, et al. Psoriatic disease treatment nowadays: unmet needs among the “jungle of biologic drugs and small molecules”. Clin Rheumatol. 2018;37:1739–1741.
   PubMed Web of Science ®Google Scholar
• Papp K, Cather JC, Rosoph L, et al. Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial. Lancet. 2012;380:738–746.
   PubMed Web of Science ®Google Scholar
• Perez-Aso M, Montesinos MC, Mediero A, et al. Apremilast, a novel phosphodiesterase 4 (PDE4) inhibitor, regulates inflammation through multiple cAMP downstream effectors. Arthritis Res Ther. 2015;17:249.
   PubMed Web of Science ®Google Scholar
• Schafer PH, Chen P, Fang L, et al. The pharmacodynamic impact of apremilast, an oral phosphodiesterase 4 inhibitor, on circulating levels of inflammatory biomarkers in patients with psoriatic arthritis: substudy results from a phase III, randomized, placebo-controlled trial (PALACE 1). J Immunol Res. 2015;2015:1–10.
   Web of Science ®Google Scholar
• Mavropoulos A, Zafiriou E, Simopoulou T, et al. Apremilast increases IL-10-producing regulatory B cells and decreases proinflammatory T cells and innate cells in psoriatic arthritis and psoriasis. Rheumatology (Oxford). 2019;58:2240–2250.
   PubMed Web of Science ®Google Scholar
• Schett G, Wollenhaupt J, Papp K, et al. Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2012;64:3156–3167.
   PubMed Web of Science ®Google Scholar
• Strand V, Schett G, Hu C, et al. Patient-reported health-related quality of life with apremilast for psoriatic arthritis: a phase II, randomized, controlled study. J Rheumatol. 2013;40:1158–1165.
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, Mease PJ, Gomez-Reino JJ, et al. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis. 2014;73:1020–1026.
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, Mease PJ, Gomez-Reino JJ, et al. Longterm (52-week) results of a phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis. J Rheumatol. 2015;42:479–488.
   PubMed Web of Science ®Google Scholar
• Cutolo M, Myerson GE, Fleischmann RM, et al. A phase III, randomized, controlled trial of apremilast in patients with psoriatic arthritis: results of the PALACE 2 trial. J Rheumatol. 2016;43:1724–1734.
   PubMed Web of Science ®Google Scholar
• Edwards CJ, Blanco FJ, Crowley J, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3). Ann Rheum Dis. 2016;75:1065–1073.
   PubMed Web of Science ®Google Scholar
• Gladman DD, Kavanaugh A, Gómez-Reino JJ, et al. Therapeutic benefit of apremilast on enthesitis and dactylitis in patients with psoriatic arthritis: a pooled analysis of the PALACE 1-3 studies. RMD Open. 2018;4:e000669.
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, Gladman DD, Edwards CJ, et al. Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1-3 pooled analysis. Arthritis Res Ther. 2019;21:118.
   PubMed Web of Science ®Google Scholar
• Wells AF, Edwards CJ, Kivitz AJ, et al. Apremilast monotherapy in DMARD-naive psoriatic arthritis patients: results of the randomized, placebo-controlled PALACE 4 trial. Rheumatology (Oxford). 2018;57:1253–1263. .
   PubMed Web of Science ®Google Scholar
• Nash P, Ohson K, Walsh J, et al. Early and sustained efficacy with apremilast monotherapy in biological-naive patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE). Ann Rheum Dis. 2018;77:690–698.
   PubMed Web of Science ®Google Scholar
• Jamilloux Y, El Jammal T, Vuitton L, et al. JAK inhibitors for the treatment of autoimmune and inflammatory diseases. Autoimmun Rev. 2019 Sep;11:102390. .
   Google Scholar
• Gao W, McGarry T, Orr C, et al. Tofacitinib regulates synovial inflammation in psoriatic arthritis, inhibiting STAT activation and induction of negative feedback inhibitors. Ann Rheum Dis. 2016;75:311–315.
   PubMed Web of Science ®Google Scholar
• Paik J, Deeks ED. Tofacitinib: a review in psoriatic arthritis. Drugs. 2019;79:655–663.
   PubMed Web of Science ®Google Scholar
• Pfizer. Xeljanz: EU summary of product characteristics. 2018. [cited 2019 October 15]. Available from: http://www.ema.europa.eu/
   Google Scholar
• Tofacitinib for psoriatic arthritis (PsA) is now approved by the European Commission. Rheumatology (Oxford). 2018;57:e55.
   PubMedGoogle Scholar
• Lu C, Wallace BI, Waljee AK, et al. Comparative efficacy and safety of targeted DMARDs for active psoriatic arthritis during induction therapy: a systematic review and network meta-analysis. Semin Arthritis Rheum. 2019;49:381–388.
   PubMed Web of Science ®Google Scholar
• Berekmeri A, Mahmood F, Wittmann M, et al. Tofacitinib for the treatment of psoriasis and psoriatic arthritis. Expert Rev Clin Immunol. 2018;14:719–730.
   PubMed Web of Science ®Google Scholar
• Sondag M, Verhoeven F, Guillot X, et al. Efficacy of new treatments for dactylitis of psoriatic arthritis: update of literature review. Clin Rheumatol. 2019;38:591–596.
   PubMed Web of Science ®Google Scholar
• Song GG, Lee YH. Comparison of the efficacy and safety of tofacitinib and apremilast in patients with active psoriatic arthritis: a Bayesian network meta-analysis of randomized controlled trials. Clin Drug Investig. 2019;39:421–428.
   PubMed Web of Science ®Google Scholar
• Asahina A, Etoh T, Igarashi A, et al. Oral tofacitinib efficacy, safety and tolerability in Japanese patients with moderate to severe plaque psoriasis and psoriatic arthritis: a randomized, double-blind, phase 3 study. J Dermatol. 2016;43:869–880.
   PubMed Web of Science ®Google Scholar
• Mease P, Hall S, FitzGerald O, et al. Tofacitinib or adalimumab versus placebo for psoriatic arthritis. N Engl J Med. 2017;377:1537–1550.
   PubMed Web of Science ®Google Scholar
• Gladman D, Rigby W, Azevedo VF, et al. Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors. N Engl J Med. 2017;377:1525–1536.
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Gladman DD, FitzGerald O, et al. Radiographic progression according to baseline C-reactive protein levels and other risk factors in psoriatic arthritis treated with tofacitinib or adalimumab. J Rheumatol. 2019;4:1089–1096.
   Google Scholar
• Strand V, de Vlam K, Covarrubias-Cobos JA, et al. Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden – a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs. RMD Open. 2019;5:e000806.
   PubMed Web of Science ®Google Scholar
• Strand V, de Vlam K, Covarrubias-Cobos JA, et al. Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL Beyond. RMD Open. 2019;5:e000808.
   PubMed Web of Science ®Google Scholar
• Nash P, Coates LC, Fleischmann R, et al. Efficacy of tofacitinib for the treatment of psoriatic arthritis: pooled analysis of two Phase 3 studies. Rheumatol Ther. 2018;5:567–582.
   PubMed Web of Science ®Google Scholar
• Helliwell P, Coates LC, FitzGerald O, et al. Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease.Arthritis. Res Ther. 2018;20:242.
   Google Scholar
• Gladman DD, Charles-Schoeman C, McInnes IB, et al. Changes in lipid levels and incidence of cardiovascular events following tofacitinib treatment in patients with psoriatic arthritis: a pooled analysis across phase III and long-term extension studies. Arthritis Care Res (Hoboken). 2019;71:1387–1395.
   PubMed Web of Science ®Google Scholar
• Van Rompaey L, Galien R, van der Aar EM, et al. Preclinical characterization of GLPG0634, a selective inhibitor of JAK1, for the treatment of inflammatory diseases. J Immunol. 2013;191:3568–3577.
   PubMed Web of Science ®Google Scholar
• Mease P, Coates LC, Helliwell PS, et al. Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial. Lancet. 2018;392:2367–2377.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Identifier: NCT03104400.
   Google Scholar
• ClinicalTrials.gov. Identifier: NCT03104374.
   Google Scholar
• Papp KA, Menter MA, Raman M, et al. A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis. Br J Dermatol. 2016;174:1266–1276.
   PubMed Web of Science ®Google Scholar
• Burke JR, Cheng L, Gillooly KM, et al. Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain. Sci Transl Med. 2019;11:eaaw1736.
   Web of Science ®Google Scholar
• Velazquez L, Fellous M, Stark GR, et al. A protein tyrosine kinase in the interferon alpha/beta signaling pathway. Cell. 1992;70:313–322.
   PubMed Web of Science ®Google Scholar
• Karaghiosoff M, Steinborn R, Kovarik P, et al. Central role for type I interferons and Tyk2 in lipopolysaccharide-induced endotoxin shock. Nat Immunol. 2003;4:471–477.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Identifier: NCT03881059.
   Google Scholar
• [cited 2019 Dec 13]. Available from: https://www.pfizermedicalinformation.com/en-us/xeljanz#S5.1
   Google Scholar
• Liu Y, Zhou S, Assaf M, et al. Impact of renal impairment on the pharmacokinetics of apremilast and metabolite M12. Clin Pharmacol Drug Dev. 2016;5:469–479.
   PubMed Web of Science ®Google Scholar
• Ceccarelli F, Lucchetti R, Perricone C, et al. Musculoskeletal ultrasound in monitoring response to apremilast in psoriatic arthritis patients: results from a longitudinal study. Clin Rheumatol. 2019;38:3145–3151.
   PubMed Web of Science ®Google Scholar